|
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Candidates Etc
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); DUBLIN - (Business Wire) Research and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the "" report to their offering.Until a decade ago...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Candidates Etc
DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the "" report to their offering.Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Candidates Etc
DUBLINResearch and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the "" report to their offering.Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners
Research and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the 'Colorectal Cancer Drug Pipeline Update 2010' report to their offering.Until a decade ago, 5FU/leucovorin formed the mainstay of...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Candidates Etc
DUBLINResearch and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the "" report to their offering.Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Candidates Etc
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the "Colorectal Cancer Drug Pipeline Update 2010" report to their offering.Until a decade ago, 5FU/leucovorin...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Candidates Etc
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the "Colorectal Cancer Drug Pipeline Update 2010" report to their offering.Until a decade ago, 5FU/leucovorin...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners
Research and Markets: - Find Competitors, Collaborations Partners & Candidates Etc DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the '' report to their...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Cand
Research and Markets: - Find Competitors, Collaborations Partners & Candidates Etc DUBLIN - (BUSINESS WIRE) - Research and Markets (http://www.researchandmarkets.com/research/391a9c/colorectal_cancer) has announced the addition of the "" report to their...
|
|
|
Research and Markets: Colorectal Cancer Drug Pipeline Update 2010 - Find Competitors, Collaborations Partners & Candidates etc
Research and Markets (http://www.researchandmarkets.com/research/f23001/colorectal_cancer) has announced the addition of the "Colorectal Cancer Drug Pipeline Update 2010" report to their offering.Until a decade ago, 5FU/leucovorin formed the mainstay of...
|
|
|
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-040
Keryx Biopharmaceuticals, Inc.announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 ...
|
|
|
Access Pharmaceuticals begins development of its Cobalamin platform to deliver siRNA therapies
Access Pharmaceuticals (ACCP: OTCBB) is an emerging specialty pharma company developing and commercializing propriety products for the treatment and supportive care of cancer patients.MuGard, its FDA approved treatment for oral mucositis, is commercially...
|
|
|
AEterna Zentaris says Keryx reaches SPA agreement with FDA for Phase III study of perifosine
- Canadian biopharmaceutical company AEterna Zentaris Inc (TSE: AEZ) said yesterday that its US partner, Keryx Biopharmaceuticals (NASDAQ: KERX), has reached an agreement with the US Food and Drug Administration (FDA) regarding a Special Protocol Assessment ...
|
|
|
AEterna Zentaris says Keryx reaches SPA agreement with FDA for Phase III study of perifosine
- Canadian biopharmaceutical company AEterna Zentaris Inc (TSE: AEZ) said yesterday that its US partner, Keryx Biopharmaceuticals (NASDAQ: KERX), has reached an agreement with the US Food and Drug Administration (FDA) regarding a Special Protocol Assessment ...
|
|
|
Keryx Biopharmaceuticals Announces Protocol Assessment Agreement With FDA For Phase 3 Trial Of KRX-0401 (Perif
Keryx Biopharmaceuticals, Inc.(Nasdaq: KERX) announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX...
|
|
|
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
NEW YORK, Feb.3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase...
|
|
|
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr.Johanna Bendell, Director, GI Oncology Research, Sarah Cannon Research Institute PR Newswire NEW YORK, Feb. 3 NEW YORK, Feb. 3 /PRNewswire-FirstCall/ ...
|
|
|
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-040
NEW YORK PHASE 3 TRIAL DESIGN: The Phase 3 X-PECT (Xeloda, + Perifosine Evaluation in Colorectal cancer Treatment) trial will be a randomized (1:1), double-blind trial comparing the efficacy and safety of perifosine + capecitabine (capecitabine is a...
|
|
|
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patie
NEW YORK, Feb.3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase...
|
|
|
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
Keryx Biopharmaceuticals, Inc.(Nasdaq: KERX) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor,...
|
|
|
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Clinical Trials & Medical Discoveries, FDA Approval Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr.
|
|
|
Keryx Biopharma (KERX) Reaches Agreement with FDA Regarding SPA on Design of Phase 3 Trial for KRX-0401
Keryx Biopharmaceuticals, Inc.(Nasdaq: KERX) announced today that it has reached agreement with the U.S. FDA regarding a Special Protocol Assessment on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients...
|
|
|
Research and Markets: Drive the Roadmap for Success in Oncology as Global Oncology Market is Projected to Outg
Research and Markets (http://www.researchandmarkets.com/research/d7939f/roadmap_for_succes) has announced the addition of the 'Roadmap for Success in Oncology' report to their offering.The worldwide oncology market is projected to outgrow the rest of the...
|
|
|
Colorectal Cancer Drug Pipeline Update 2010
Published Date: January 2010 Published By: Order Code: R474-371 Description Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard...
|
|
|
Poniard shares fall after cancer drug shows lower survival
Jan 25 (Reuters) - Shares of Poniard Pharmaceuticals Inc <PARD.O> fell as much as 21 percent on Monday as its cancer drug picoplatin showed lower overall survival rate in a mid-stage trial, although the drug met its main goal.The mid-stage trial tested...
|
